POSTER SESSION: Postertalks will be selected on Thurday between 18:15-21:00 during the postersession. On Friday morning it will be announced who is going to present when. Postertalks will be held on Frieday between 13:40-15:00. | |||
Gene vector development and targeting | |||
P1 | Capsid-engineering overcomes barriers toward endothelial cell transduction | Zhang, L.A. | |
P2 | Improving AAV gene therapy safety analysis: Multiplex LAM-PCR provide new insights into AAV vector integration | Gil Farina, Irene | |
P3 | Enhanced rAAV in vivo transduction efficacy in endothelium via surface modified PAMAM coating | Lee, Seungmin | |
P4 | AAV wild-type and rAAV vector-mediated genomic integration profiles in human diploid fibroblasts analyzed by 3rd generation PacBio DNA sequencing | Heilbronn, Regine | |
P5 | Production of safe and efficient AAV vectors using minicircle DNA | Schleef, Martin | |
P6 | Novel subventricular zone early progenitor cell specific adenovirus for in situ brain stem cell bioengineering unveils cellular heterogeneity | Pützer, Brigitte | |
P7 | Reduced macrophage activation by HUVEC upon magnetic microbubble-mediated transduction with vIL10- encoding AdV | Anton, Martina | |
P8 | Receptor-targeted lentiviral vectors are exceptionally sensitive towards the biophysical properties of the displayed single-chain Fv | Schneider, Irene | |
P9 | Fluorescent Nanoparticle Tracking Analysis (NTA) characterization of Lentiviral Vectors by size and composition | Uhlig, Joerg | |
P10 | Selective gene delivery into human iPS cells based on CD30-targeted lentiviral vectors | Friedel, Thorsten | |
P11 | Proof-of-concept studies for post-exit immune-modulatory modifications of lentiviral vector particles. | Metzner, Christoph | |
P12 | Integration-neutral betaretrovirus-based vector with split-genome design for transduction of dividing and non-dividing cells | Indik, Stanislav | |
P13 | Multiplex Real-Time PCR assay for the detection and differentiation of poxviruses | Stellberger, Thorsten | |
P14 | siRNA for polypharmacology in cancer cell lines | Baumann, Volker | |
P15 | A new hybrid vector system for enhanced osteogenic gene therapy | Hacobian, Ara | |
P16 | Synthetic Nucleases for Drug Resistance Mutational Screens | Rath, Tim | |
P17 | Genetic and functional correction of the human deltaF508 CFTR locus using designer nuclease technology | Bednarski, Christien | |
P18 | A minimal ubiquitous chromatin opening element (UCOE) effectively prevents silencing of juxtaposed heterologous promoters by epigenetic remodeling in multipotent and pluripotent stem cells | Müller-Kuller, Uta | |
P19 | The interaction of autonomous replicons with the host genome | Hagedorn, Claudia | |
P20 | Development of universal PCR-based strategies for the identification of transgenes encoded by commonly used viral vectors | Baiker, Armin | |
P21 | Primary porcine endothelial cells as a convenient in vitro toxicity 96-well based assay for polycations | Gehrig, Sebastian | |
Molecular imaging | |||
P22 | Twodimensional vs. threedimensional analysis of transient reportergene expression in vivo with optical imaging | Gehrig, Sebastian | |
P23 | Near-infrared emitting fluorescent proteins as useful reporter genes for transient transfection studies | Taschauer, Alexander | |
Oncolytic viruses | |||
P24 | Development of oncolytic measles virus with immunomodulatory transgenes | Veinalde, Ruta | |
P25 | LCMV-GP Chimeric Oncolytic Vesicular Stomatitis Virus for the Treatment of solid tumors | Urbiola, Carles | |
P26 | Engineering BiTE-armed oncolytic measles viruses for cancer immunovirotherapy. | Speck, Tobias | |
P27 | Tumor-vaccines based on oncolytic measles virus | Muehlebach, Michael | |
P28 | Chimeric VSV for safe intracranial application | Wollmann, Guido | |
Cancer immune(gene) therapy and cancer vaccines | |||
P29 | Redirection of T cells against cells expressing HBsAg | Festag, Marvin | |
On the road towards clinical application | |||
P30 | Biodistribution of Advanced Therapy Medicinal Products (ATMPs): Workflow of a typical study at a professional pre-clinical service provider | Schreieck, Amelie | |
Gene Therapy for chronic diseases | |||
P31 | The Silencing by Chitosan/PDGF-B Nanoplexes of Mesangial Cell Proliferation in Renal Disease | Salva, Emine | |
P32 | Correction of COL7A1 mutations in a human RDEB patient cell line by 3' trans-splicing | Tockner, Birgit | |
P33 | Design and in vitro testing of Sleeping Beauty Transposon vectors for Gene Therapy of Cystic Fibrosis | Walisko, Oliver | |
Latest developments in cell- and gene therapy | |||
P34 | Modified messenger RNA and its application in bone tissue engineering | Ferizi, Mehrije | |
P35 | Auxotrophy complementation for antibiotic-free plasmid stabilization | Velur Selvamani, Ram Shankar | |
P36 | Highly Specific Nucleases to target the RPGR Gene for Gene Therapy | Yanik, Mert |